We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current SHPMY market cap is 5.55B. The company's latest EPS is CNY 5.0940 and P/E is 0.29.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 186.02B | 191.32B | 215.16B | 231.27B | 259.56B |
| Operating Income | 26.27B | 26.84B | 27.88B | 29.77B | 30.59B |
| Net Income | 4.08B | 4.5B | 5.09B | 5.62B | 3.77B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 137.03B | 149.19B | 163.44B | 198.13B | 211.97B |
| Total Liabilities | 87.64B | 94.44B | 104.37B | 120.13B | 131.65B |
| Total Equity | 49.39B | 54.74B | 59.07B | 78B | 80.33B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | 6.02B | 6.84B | 5.06B | 4.74B | 5.23B |
| Investing | -4.58B | -1.71B | -6.02B | -12.47B | -2.49B |
| Financing | -2.33B | -1.26B | 1.57B | 12.14B | 231.85M |
| Market Cap | 5.55B |
| Price to Earnings Ratio | 0.29 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.04 |
| Price to Book Ratio | 0.01 |
| Dividend Yield | - |
| Shares Outstanding | 739.7M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.71 (8.74%) |
| Company Name | Shanghai Pharmaceuticals Holdings Company Ltd (PK) |
| Address |
shanghai pharma building shanghai 200020 |
| Website | https://www.sphchina.com |
| Industry | medicinal chems,botanicl pds (2833) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
